about
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicityNek4 status differentially alters sensitivity to distinct microtubule poisonsPaclitaxel-dependent cell lines reveal a novel drug activity.New insights into mechanisms of resistance to microtubule inhibitorsKIFC1: a promising chemotherapy target for cancer treatment?Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation TherapyKatanin localization requires triplet microtubules in Chlamydomonas reinhardtiiHigh expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancerChemoresistance and targeted therapies in ovarian and endometrial cancersGenes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signalingMegakaryocyte lineage-specific class VI β-tubulin suppresses microtubule dynamics, fragments microtubules, and blocks cell division.Alterations in ovarian cancer cell adhesion drive taxol resistance by increasing microtubule dynamics in a FAK-dependent manner.A label-free mass spectrometry method for relative quantitation of β-tubulin isotype expression in human tumor tissue.Induction and characterization of taxol-resistance phenotypes with a transiently expressed artificial transcriptional activator library.Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathwayPaclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancerCo-delivery of paclitaxel and tetrandrine via iRGD peptide conjugated lipid-polymer hybrid nanoparticles overcome multidrug resistance in cancer cells.Kanglaite sensitizes colorectal cancer cells to Taxol via NF-κΒ inhibition and connexin 43 upregulationTubulin proteomics: towards breaking the code.Potentiation of taxol efficacy and by discodermolide in ovarian carcinoma xenograft-bearing miceComparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells.Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress.Distinct pose of discodermolide in taxol binding pocket drives a complementary mode of microtubule stabilization.Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transitionMicrotubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancerIn vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.FoxM1 mediates resistance to herceptin and paclitaxel.FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells.MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers.Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarityEpstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol)Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance.βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancerPhase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemiaCharacterization and detection of cellular and proteomic alterations in stable stathmin-overexpressing, taxol-resistant BT549 breast cancer cells using offgel IEF/PAGE difference gel electrophoresis.Clinical trials and progress with paclitaxel in ovarian cancer
P2860
Q24547477-2BD19B05-1FDC-4769-BFF1-5B4D47B247CCQ24600436-B8076B98-0928-4A26-B358-C4EBA6E971BAQ24608070-73D62B80-AD44-485E-8046-0F76C94DFD6CQ24633853-0EBDEAF7-7098-4375-8C3F-1097622BF76DQ26751207-F9BE197D-02DA-4A9E-AFE2-598933D1118FQ26775004-51F0E65C-2F28-4910-BF9B-5F9A5479C91DQ27320598-3B8DF15F-B709-4A97-A49A-C9E37134AEA0Q27851983-FF3693CC-8F3B-4EBE-BEE8-1296E40A0DD3Q28073246-0AEBFCD1-E0A5-49F0-9C59-5EBDDD5ECA80Q28289659-73604661-C945-4011-B046-1A007BEA4AC4Q30428045-AC396BA0-D880-4054-A747-F56D6CF82BF4Q30640795-47BF1FEF-40EC-463D-B319-4CD4A5543BEEQ31097343-C4345AA8-391C-4BFB-8E4A-3923205856FEQ33205727-AE62694B-3F7C-4D44-9BB1-57ECE64452E1Q33575279-8C6FAD23-DF60-49E3-90E0-E0611460EED3Q33586121-C13C5DD9-5075-4057-B7B9-5F2530A7AA4BQ33634653-C2725295-AB40-4C28-8447-D52F68146D2EQ33682756-26389106-60FE-4D50-B960-051CEC7E6F77Q33687990-DF261E7F-3C31-4DAC-8824-57886059A731Q33688024-5398636C-D95E-45CC-B863-CBAB6ED92EFFQ33728576-150C5D81-AC1F-4DF4-9F01-567D11B5CBCDQ33746588-76ED393F-D87F-41EC-A124-0E9A4A05C9E7Q33752976-4C31072F-986A-4926-87A4-C805E35FC745Q33829740-9ED21B2E-2F8D-4BED-87E7-C7F0F5B1FB63Q33852049-32446780-30D6-4B84-BC65-0231CA05316BQ33918055-365D564A-905A-4E8A-B7B6-0735EFE2C568Q33921296-8F11D77B-44D6-4F3F-B16D-AB9AAA271711Q33946664-D8F59D28-E542-4733-9412-3D83A79655E6Q33991617-9D1BEA9D-FA0B-48A7-90B1-710C331AE6FBQ34104738-3724608F-568F-47A0-9397-DE50826067B0Q34111215-912B5B8F-200A-402A-B883-7A11DAC8C34EQ34148034-252C9E23-3161-48BC-AE53-B570A7D0DAB4Q34154782-44D97900-23D1-4DCB-B319-E6105B089352Q34169164-230E13FE-67DB-41A1-9028-B064CB224377Q34301695-A46B51EA-3D02-48F7-9576-5A92B6937A51Q34339902-E4E7BCBD-035D-4131-854E-671D549356A2Q34353248-FF50DCCF-83D1-4A00-82FE-1549F7EE46F6Q34385571-10920835-BD86-4212-B8EE-931E3B06F3A7Q34472289-804BFD05-A0FC-4C76-9606-F302ECF28000Q34510070-8542B680-1C01-4294-9C85-1A0607A4B1D6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Mechanisms of Taxol resistance related to microtubules.
@ast
Mechanisms of Taxol resistance related to microtubules.
@en
type
label
Mechanisms of Taxol resistance related to microtubules.
@ast
Mechanisms of Taxol resistance related to microtubules.
@en
prefLabel
Mechanisms of Taxol resistance related to microtubules.
@ast
Mechanisms of Taxol resistance related to microtubules.
@en
P2860
P356
P1433
P1476
Mechanisms of Taxol resistance related to microtubules
@en
P2093
George A Orr
Hayley McDaid
P2860
P2888
P304
P356
10.1038/SJ.ONC.1206934
P407
P577
2003-10-01T00:00:00Z
P5875
P6179
1020149346